Phase II study confirms efficacy of Bavarian Nordic's Covid-19 vaccine

A study of 103 people who had previously received the vaccine found that it offers protection against all variants of the coronavirus – however, the trial took place before the Omicron variant was discovered.

Photo: Philip Davali/Ritzau Scanpix

On Sunday, Bavarian Nordic publicized results from its phase II study of its corona vaccine, ABMCoV, which it has inlicensed from biotech company Adaptvac.

Two weeks after receiving the vaccine, up to 40 times more antibodies were detected in study participants than at the start of the trial.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs